NVE 코퍼레이션 2027 회계연도 2분기 실적 발표회: 유통업체 매출 67% 증가
NVE 코퍼레이션의 2027 회계연도 2분기 매출은 대형 의료기기 고객사의 단기 재고 조정으로 인해 전년 동기 대비 8% 감소했습니다. 순이익은 317만 달러를 기록했습니다. 반면 유통업체 매출은 업황 개선에 힘입어 67% 증가했습니다.
경영진은 3분기에 의료기기 및 국방 부문 매출이 회복될 것으로 예상하고 있으며, 하반기 매출은 상반기와 유사한 수준을 유지할 것으로 전망하고 있습니다. 또한 웨이퍼 레벨 칩 스케일 센서의 초기 설계 수주를 달성했으며, 로보틱스와 전력 변환 시장에서 수요가 증가할 것으로 기대하고 있습니다.
핵심 요약
- NVE 코퍼레이션의 2027 회계연도 2분기 매출은 대형 의료기기 고객사의 단기 재고 조정으로 인해 제품 판매가 9% 감소하면서 전년 동기 대비 8% 하락했습니다.
- 업황 개선과 신규 및 기존 상업용 제품 모두에 대한 수요에 힘입어 유통업체 매출은 전년 동기 대비 67% 증가했습니다.
- 순이익은 317만 달러(희석주당 0.65달러)로 전년 동기의 331만 달러(주당 0.68달러) 대비 감소했습니다. 순이익률은 54%, 매출총이익률은 78%를 기록했습니다.
- 2027 회계연도 상반기 매출은 36% 증가한 1,690만 달러를 기록했습니다. 상반기 순이익은 957만 달러(희석주당 1.97달러)에 달했습니다.
- 경영진은 3분기에 의료기기 및 국방 부문 매출이 회복될 것으로 예상하며, 하반기 매출은 상반기와 비슷한 수준을 유지할 것으로 전망하고 있습니다.
- NVE는 웨이퍼 레벨 칩 스케일 센서의 초기 설계 수주(design win)를 달성했으며, 산업용 자동화, 전력 변환 및 휴머노이드 로보틱스 고객사들의 관심이 높아지고 있다고 밝혔습니다.
주요 재무 데이터
| 지표 | 2027 회계연도 2분기 실적 | 전년 동기 대비 변동 또는 맥락 |
|---|---|---|
| 총매출 | 명시되지 않음 | 8% 감소 |
| 제품 매출 | 명시되지 않음 | 9% 감소 |
| 계약 R&D 매출 | 명시되지 않음 | 25% 증가 |
| 유통업체 매출 | 명시되지 않음 | 67% 증가 |
| 매출총이익률 | 78% | 견조한 수준 유지 |
| 영업비용 | 명시되지 않음 | 4% 증가 |
| 판매관리비 | 명시되지 않음 | 이사 스톡옵션 부여 시 주가 상승으로 인해 44% 증가 |
| 연구개발비 | 명시되지 않음 | 17% 감소 |
| 실효세율 | 14% | 20%에서 감소 |
| 순이익 | 317만 달러 | 331만 달러에서 감소 |
| 희석 주당순이익(EPS) | $0.65 | $0.68에서 감소 |
| 순이익률 | 54% | 낮아진 실효세율 수혜 |
| 상반기 매출 | 1,690만 달러 | 36% 증가 |
| 상반기 순이익 | 957만 달러 | 희석주당 1.97달러 |
| 상반기 영업활동 현금흐름 | 1,110만 달러 | 800만 달러에서 증가 |
| 현금 및 유가증권 | 4,440만 달러 | 4,350만 달러에서 증가 |
매출채권은 고객 결제 시점에 따라 12% 감소한 반면, 재고자산은 상반기 제품 판매 증가에 따라 3% 감소했습니다. 해당 기간 영업활동 현금흐름으로 배당금 지급과 고정자산 매입을 충당했습니다.
사업 및 영업 실적
분기 매출 감소는 새로운 차질이라기보다는 주문 시점의 차이를 반영한 것입니다. 경영진은 대형 의료기기 고객사의 주문이 주로 2분기에서 1분기로 앞당겨졌다고 설명했습니다. 매출은 분기 말로 갈수록 회복되어 9월 매출이 8월을 상회했습니다.
유통업체 실적은 주요 긍정적 지표였습니다. 2분기 유통업체 매출은 전년 동기 대비 67% 증가하여 경영진의 상반기 예상치인 약 40% 성장을 상회했습니다. 회사 측은 유통업체 비중이 높아지면 직접 판매보다 이익률이 낮아질 수 있지만, 유통업체 매출은 자사 제품 포트폴리오 전반을 광범위하게 반영한다고 설명했습니다.
NVE는 이번 분기 동안 두 가지 제품군을 선보였습니다. 신제품인 웨이퍼 레벨 칩 스케일 센서는 0.55mm² 크기로 소형 폼팩터와 높은 감도를 결합하여 의료기기, 산업용 자동화 및 로보틱스의 정밀 모션 애플리케이션에 적합합니다. 또한 산업용 자동화 및 로보틱스의 모션, 속도, 위치 감지를 위해 설계된 7가지 버전의 기어 센서를 출시했습니다.
경영진은 전력 변환을 또 다른 성장 시장으로 강조했습니다. NVE는 실적 발표에서 언급된 800V 아키텍처로의 전환을 포함해 전원 공급 장치 및 전력 변환 시스템의 응용 전압이 높아짐에 따라 자사의 고절연 제품이 수혜를 입고 있다고 밝혔습니다.
의료기기 분야에서 NVE는 신경 자극기를 포함한 기타 이식형 제품으로 성장을 모색하는 동시에 심장 리듬 관리 애플리케이션에 대한 공급을 지속하고 있습니다. 경영진은 작은 크기와 낮은 전력 소비를 해당 애플리케이션의 핵심 강점으로 꼽았습니다.
경영진 전망(가이던스)
경영진은 2027 회계연도 3분기에 의료기기 및 국방 매출이 회복되고 이번 분기에 성장세로 돌아설 것으로 예상하고 있습니다. 상반기 실행률(run rate)을 가이던스의 기준으로 삼아, 하반기 매출은 상반기 매출과 유사한 수준이 될 것으로 전망하고 있습니다.
NVE는 우호적인 세법 개정을 반영해 적어도 2027 회계연도의 잔여 기간 동안 실효세율이 14%에서 16% 사이를 유지할 것으로 예상합니다.
회사는 직접 채널과 유통 채널, 기존 제품과 신제품 전반에서 광범위한 성장이 지속될 것으로 기대합니다. 다만 경영진은 초기 설계 수주는 통상 샘플 및 수천 개 단위의 주문으로 시작하여 향후 10배 이상 증가할 잠재력이 있다고 강조했습니다. 이러한 수량 확대에는 수 분기가 걸릴 수 있습니다.
리스크 및 주목할 점
- NVE는 매출의 상당 부분을 소수의 대형 고객사에 의존하고 있어 분기 실적이 조달 시점과 재고 조정에 민감하게 반응합니다.
- 의료기기 주문 패턴은 정부 조달 주기 때문에 단기적인 매출 변동성을 유발할 수 있습니다.
- 경영진은 통상 수주 잔고를 추적하지 않으므로 향후 주문 커버리지에 대한 가시성이 제한적입니다.
- 웨이퍼 레벨 칩 스케일 센서 및 로보틱스 관련 기회는 아직 초기 샘플링, 시제품 제작 또는 시스템 통합 단계에 있으며, 고객의 생산 일정은 불확실합니다.
- 유통업체 매출은 매출 유연성과 시장 접근성을 넓힐 수 있지만, 마진이 더 낮은 매출 구조를 형성할 수 있습니다.
- 회사는 최종 시장의 경제 환경 불확실성과 향후 판매 및 매출에 대한 불확실성을 언급했습니다.
애널리스트 Q&A 주요 내용
경영진은 웨이퍼 레벨 칩 스케일 제품이 여러 건의 초기 설계 수주를 확보했다고 밝혔습니다. 초기 구매는 일반적으로 샘플 또는 수천 개 단위로 이뤄지며, 고객사가 시스템 수준의 통합을 완료한 후 더 큰 주문이 가능해집니다. NVE는 관심과 주문 규모가 늘고 있다고 밝혔으나 특정 고객에 대한 세부 정보는 제공하지 않았습니다.
휴머노이드 로보틱스의 경우 신형 기어 센서는 첨단 엔코더 및 서보 시스템을 겨냥하고 있습니다. 경영진은 서구권 및 기타 글로벌 고객사들로부터 관심을 받고 있다고 전했습니다. 일반적인 NVE 센서의 평균 판매 가격(ASP)은 약 1달러에서 2달러 수준이며, 경영진은 휴머노이드 로봇 1대에 "수십 개"의 센서가 사용될 수 있다고 말했습니다.
NVE는 수백만 개에서 수천만 개의 센서를 생산할 수 있으며, 고객의 생산 확대에 따라 그 이상으로 확장할 수 있다고 설명했습니다. 케파 증설을 통해 확보한 설비의 일부는 특히 웨이퍼 레벨 칩 스케일 제품을 중심으로 R&D에서 양산으로 전환되기 시작했지만, 그 비중은 아직 상대적으로 작은 수준입니다.
피터 임스(Peter Eames) 사장 겸 CEO 체제 하에서 경영진의 장기 전략은 최근의 생산능력 확대를 활용해 빠르게 성장하는 시장을 위한 제품을 개발하는 것입니다. 우선순위 분야로는 로보틱스, 전력 변환, 사물지능융합기술(AIoT) 등이 있습니다. 또한 회사는 특허 포트폴리오, 영업 비밀 및 자체 스핀트로닉스 전문성이 진입 장벽을 형성한다고 밝혔습니다.
실적 발표 전화회의 전문
전체 실적 발표 컨퍼런스 콜 녹취록
경영진 발표
Peter Eames
Good afternoon, and welcome to the NVE Corporation conference call for the quarter ended September 30, 2026. I'm Pete Eames, NVE's President and CEO. With me on the call is Daniel Nelson, our Principal Financial Officer. This call is being webcast live on YouTube and Google Meet and being recorded. A replay is available through our website, nve.com, and our YouTube channel, uube.com/nveorpor. After my opening comments, Daniel Nelson will present our financial results, then I'll cover the business. I'll also cover the recent leadership transition and Board expansion, and then we'll open the call to questions. We issued our press release with summary financial results and filed our quarterly report on Form 10-Q in the past hour following the close of market.
Links to the press release and 10-Q are available through our website, the SEC's website. NX, formerly known as Twitter. Please refer to the safe harbor statement on your screen Comments we may make that relate to future plans, events, financial results or performance are forward-looking statements that are subject to certain risks and uncertainties, including, among others, such factors as our reliance on several large customers for a significant percentage of revenue, uncertainties related to the economic environments in the industries we serve, uncertainties related to future sales and revenues as well as risk factors listed from time to time in our filings with the SEC, including our annual report on Form 10-K for the year ended March 31, 2026.
Actual results could differ materially from the information provided, and we undertake no obligation to update forward-looking statements we may make. We're pleased to report solid revenue and earnings for the quarter, driven by a 67% increase in distributor sales. Net margins increased to 54% due to a decrease in our effective tax rate. Daniel Nelson will cover the details of the financials. Daniel?
Daniel Nelson
Thanks, Pete. Total revenue for the quarter decreased 8% compared to the prior year quarter. The decrease was due to a 9% decrease in product sales, partially offset a 25% increase in contract R&D revenue. The decrease in product sales was due to a short-term inventory adjustment at one of our large medical device customers. Inventory adjustments by medical device customers can create short-term auto because of government procurement cycles. Looking forward, -- we expect medical device and defense sales to recover in the current quarter, and we expect revenues in the second half of the fiscal year to be consistent with the first half.
Aside from the short-term order flow adjustment in Medical, we saw a 67% increase in distributor sales due to strengthening industry conditions and strong demand for our new and legacy commercial products. The increase in contract R&D revenue in the past quarter was due to progress on existing contracts. Total operating expenses increased 4% for the second quarter of fiscal 2017 compared to the second quarter of fiscal 2026 due to a 44% increase in selling, general and administrative expense, partially offset by a 17% decrease in R&D expense. The increase in SG&A was due to higher director option granted stock prices.
Our effective tax rate, which is the provision for income taxes as a percentage of income before taxes decreased to 14% from 20% in the prior year quarter, primarily due to favorable tax law changes. The decrease is consistent with our previous estimates, and we expect our effective tax rate to be between 14% and 16% for at least the remainder of the fiscal year. Net income for the second quarter of fiscal 2027 was $3.17 million or $0.65 per diluted share compared to $3.31 million or $0.68 per share in the prior year quarter. Our profitability metrics for the quarter remained strong. In adjoin to the 54% net margin, Pete mentioned previously, gross margin was 78% -- for the first 6 months of fiscal 2027, total revenue was $16.9 million, up 36% over the same period in fiscal 2026.
The increase in revenue was due to strong sales across our product portfolio as well as increases in both direct and distributor sales. Net income was $9.57 million, or $1.97 per diluted share for the first 2 quarters of fiscal 2027. Turning to cash flow items. Cash flow from operations was $11.1 million for the first 6 months of fiscal 2020 compared to $8 million for the first 6 months of fiscal 2026. Cash plus marketable securities increased from $43.5 million to $44.4 million as operating cash flow more than cover our dividends and purchases of fixed assets for the first half of the fiscal year.
Receivables decreased 12% due to timing of customers' payments. Inventories decreased 3% due to increased product sales in the first half of the fiscal year and we pay our $1 per share quarterly dividend in the past quarter and declared another dividend to be paid at the end of November. Now I'll turn the call back over to PDM to cover the business, Pete?
Peter Eames
Thanks, Daniel. Our R&D strategy is to transition the world's best technology into the world's best products for high-value markets such as advanced automation and robotics, data centers and highly automated fourth wave factories using the artificial intelligence of things. This quarter, we announced 2 new products. The first is a new design in our series of wafer level chip scale sensors. The sensor provides analog information such as position from the motion or changes of external magnetic fields. These sensors are the smallest products we've ever made at NVE, measuring just 0.55 millimeter square combined with a small size is an extremely high sensitivity -- this combination enables unmatched spatial sensitivity for precision motion applications, including medical devices, industrial automation and robotics.
We are promoting our new products on YouTube with video showing the sensor detecting tiny motions of minute magnets. And you can view these videos on our website. We also released a family of gear sensors in the past quarter for precise motion speed and position sensing in industrial automation and robotics. These sensors are biased by a small magnet and detect the motion of gear teeth as they pass the sensor. 7 different versions of these sensors match common gear sizes in a newly available sensor form factor. The new sensors provide large it in factory automation and robotics, we have videos of these new products on our website and YouTube channel show incredible small size, high precision and versatility of our new sensors.
In addition to these new product launches, we're developing several new products, including even more precise answers for robotics and more power addition isolators and power conversion. Next, I'll cover our recent leadership transition and Board expansion. I was elected Director and appointed President and CEO at our Annual Shareholders' Meeting in August. Former CEO, Dan Baker, replaced Terry Glarner, Chairman. We also elected a new Director, Carolyn Valentine, expanding the board from 5 to 7 directors. The larger Board strengthens our governance. I'm honored to lead NVE as CEO. And -- we have a talented team to customer relationships and many exciting opportunities ahead.
I look forward to building on our momentum to create long-term value for our shareholders through profitable growth and expansion in attractive markets. We see significant opportunities in robotics, power conversion and the artificial intelligence of things. Now we'd like to open the call for questions via Google Meet.
질의응답
Unknown Analyst
I'd love if you can give some more color on the rescheduled orders here. So you guys attribute the decline to customer rescheduling orders. Were those pushed out into H2 and not necessarily into like next fiscal year. Were they roughly the size of the shortfall or smaller? The quarter-over-quarter shortfall are smaller than that?
Peter Eames
Yes. Sure, Ketan. The order variability was primarily from orders being pulled into quarter 1 from quarter 2. So we don't see any further disruptions looking forward. And as Daniel said in the prepared remarks, it's a relatively short-term effect.
Unknown Analyst
Okay. And following up there, -- it seems just like from shipments look weighted towards September. Would you say that September was the strongest month of the quarter? And do you guys have any other commentary around H2 velocity versus H1?
Peter Eames
Sure. Maybe Daniel can comment on receivables. .
Daniel Nelson
Yes. So in response to that question, we did see revenue increased towards the end of the September quarter. And yes, we did see increase in September compared to the immediate month, which was August.
Unknown Analyst
Got it. Got it. I'll jump back in the queue. I have other questions, but I'll let others ask before me.
If there's not, I'll ask more.
Peter Eames
Please go ahead.
Unknown Analyst
Great. So would you guys give some color around the growth we're seeing in the automation market and then as well as the power conversion markets versus your core medical sales in H1, and can you also give commentary about how that's looking into H2?
Peter Eames
Yes, we're definitely seeing strong growth in both power conversion and in robotics applications. We highlighted some important products in the prepared remarks, especially focused on automation and new sensors that go into robotics applications. So the special sensitivity that we're providing with those devices is unmatched in the industry. And we're optimistic partly because of that -- we also have excellent -- we have a high level of inventory, and we think the market is time right for robotics applications and power conversion applications. So it's driving overall optimism on our part.
Unknown Analyst
Great. Could you give some color on maybe any design wins or design ins that you have that could be driving the growth through H2 and even into the next fiscal year?
Peter Eames
Yes. For the wafer-level chip scale parts that we talked about in the prepared remarks and on the previous investor calls as well, we do have some important small design wins for those products. So it's still early there, but I think the feedback from the industry has been very positive, and we're expecting growth long term from those parts and those technologies in general.
Unknown Analyst
Okay. When you say small design wins, is that small in terms of revenue? Or is that like -- can you maybe describe the size of the customers?
Peter Eames
So when we say small design wins, it's usually in markets that start small with samples and then later move into low 1,000 quantity purchases while they work out system-level integration challenges. That can take some time. Sometimes it takes a couple of quarters, sometimes less -- for those to then translate into larger orders, factors of 10 larger than than the sample orders I described. So it does take some time to ramp up. And I would say that we're certainly within that cycle with several products. And that's why we're we're optimistic.
Unknown Analyst
Okay. So those costs -- when you say small, it's simply given that it's more sampling and prototyping volumes. Would you give any color on customer size, like who these customers are -- is there any directional understanding of like on the robotics side, are these top 5 OEMs on the maybe factory arms or humanoid side? Do you have any additional color you can give on the size of these -- of these potential customers?
Peter Eames
Yes. It's unusual for us to comment specifically on customers, but I can say that there's a variety of customers interested in the technology that spans beyond that, and we like the potential for very high volumes there.
Unknown Analyst
Would you size very high volumes?
Peter Eames
Certainly, yes. We're certainly chasing very high volumes.
Unknown Analyst
Would you be able to put like any like directional numbers to that, like what you guys are targeting?
Peter Eames
Well, we're certainly not unfamiliar with producing millions of sensors and tens of millions of sensors or certainly well within our capacity here, we can easily scale well beyond that as well in the short term and certainly within the time scale that we expect these customers to ramp up.
Unknown Analyst
Got it. Okay. On the power conversion side, on the 800-volt you've discussed that step-ups in voltage kind of raise your dollar content -- and many of the PSUs, if you look, you'd see NDs parts to some degree. Would you be able to give more color on the power conversion side on the progress as data centers are transitioning to 800-volt and your progress with your customers there?
Peter Eames
Happy and happy to highlight the advantages that NV provides as the application voltages continue to increase. We provide the highest isolation in the industry and as voltages increase in power supplies and power conversion applications, that continues to favor NVE's products, and we're continually optimistic for that reason. So we see the trends favoring NVE's technology and we're expecting continued growth there as well.
Unknown Analyst
I like the only person that's going to ask you questions. So Pete, this is Peter calling from Florida. I did a great job on your continued success there. My question is that are NVE sensors applicable to gears for humanoid robots. You mentioned robotics. It could be armed in automation and factories. But what about humanoid robots? Is that something where your sensors can be used? And is that -- are you having any conversations there?
Peter Eames
Yes. Definitely, the new gear sensors that I talked about on the call are especially intended towards robotics -- both industrial and humanoid robotics. They're intended for advanced encoders and servo systems. And those are exactly what are being used in humanoid robotics and elsewhere. So we think that the timing of that introduction is perfect with the growth in the humanoid robotics industry, and we're seeing some strong interest there already. So as Hinesaid previously, we're optimistic about those applications.
Unknown Analyst
I just wanted to ask -- just so I heard you right, you basically said that the second half in terms of top line should be similar to the first half of the year. Is that correct?
Peter Eames
That's correct. That's what we said in the prepared remarks. We do see the order disruptions as a temporary situation and we expect to return to growth in the next quarter.
Unknown Analyst
Got it. And so my follow-up would be, how do these new products and the secular growth market fit into those expectations, if you will. Is this are you guys forecasting the back half based on existing orders? Or is there still orders to go get from these new products and new use cases.
Peter Eames
Yes. We're definitely seeing more orders come in. And as Daniel said in the prepared remarks, the growth is across our product portfolio, including distributors and direct sales and legacy products and also our new products. So we're happy with the growth there, and we expect that to continue.
Unknown Analyst
So I guess asked another way, what would be, call it, upside to those internal expectations of a similar second half? Like what are some things you think could drive upside there?
Peter Eames
Well, generally, I think the market we're seeing is continuing to accelerate. We just got Abbott's numbers this morning, for example, and they project a 10% year-over-year increase. So short term, we're not seeing any further disruptions in our current sales. And I think long term, -- we have impressive products and important customers and long-term growth for those types of customers.
Unknown Analyst
Is there any color you can give on backlog or backlog coverage or any metrics you could share there, that would be helpful.
Peter Eames
Yes. We typically don't track backlog. I'd say we typically have a strong order flow, and we have plenty of inventory to satisfy those expected orders, and I think we're in good shape there.
Unknown Analyst
And then last one for me would be and you'd speak to the capacity expansion and how that's going. I recall last quarter, you mentioned it was mostly R&D for the time being, has that moved into volume production in earnest? Or any color on that would be helpful.
Peter Eames
Yes. There certainly has been some shift towards production capacity with the additional resources from the expansion. I'd say the shift is relatively small now, but as a mentioned previously, there are some important design wins in our wafer level chip scale products. And that capacity is primarily from what we've added from the expansion. So that's good news, and we'll continue to transition capacity in that direction as the order flows increase here.
Unknown Analyst
I remember last quarter, you mentioned that -- there was a bunch of new customers that start out small. I was just wondering if there is any growth in those new customers?
Peter Eames
Yes. In general, I think the trends are definitely moving in the right direction. And as I described earlier, it's common for some of those new customers to start with relatively small orders and grow over time. And we're definitely seeing that. And specifically, in the products that I mentioned in the prepared remarks and in the wafer level chip scale products. We're seeing a continual increase in the interest and increases in order size. So it's definitely moving in the right direction.
Unknown Analyst
And these new customers are mostly in the new industries you were talking about like robotics, correct?
Peter Eames
Yes. Robotics and automation and factory automation and humanoid robotics are 2 important areas where we're seeing that interest.
Unknown Analyst
I am among relatively new independent investor. I just congratulations on your new role and Curious to know, in terms of the long-term horizon of the company over the next 2 to 3 years. What is your sort of vision now for the company? Is it going to defer? Is it going to be a little bit different from what your predecessor was doing? And how should investors think about the company going forward?
Peter Eames
I would say the main focus for me is taking advantage of the recent expansion and leveraging that towards new products and new products in fast-growing markets. So it's a continuation of our previous efforts and my efforts on the expansion in general. But I'd say it's a continuation in the trajectory that was started under Dan's leadership and moving to take advantage of that expansion.
Unknown Analyst
And then on the medical device portion of the revenue, I know that sort of strong percentage of that is coming from Abbott right now. Is there a focus on sort of diversifying that out? Or how do you think about that?
Peter Eames
We definitely work to expand our products throughout the medical device industry. So cardiac rhythm management and Abbott obviously is an important a customer of ours, but we see growth in other areas as well, other implantable medical devices such as neurostimulators, are important growth areas for NV's products as well. And it's because we have the advantages of small size and low power makes us a perfect technology for implantable medical devices.
Unknown Analyst
Final question here for me. Would you say that your humanoid robotics customers are planning to be entering production volumes in 2027 or even in 2026 at the tail end of this year?
Peter Eames
It's hard to say. We talk to our robotics customers regularly, and there is definitely a forecast for growth there. It's hard to speak directly to what their plans are. But we do see increasing production on our side, and we're happy to report that those are moving in to those types of applications, so automation and humanoid robotics. So generally, I think we're aligned well with the industry and the specific needs for the robotics market. And we'll continue to see things move in that direction.
Unknown Analyst
And my final, I guess, question on the human on robotics front, two-pronged here. Would you say most of your humanoid robotics customers are Western OEMs? And would you be able to like size the relative dollar content per robot that you guys are expecting, even if it's a range?
Peter Eames
Sure. Yes. So we have a global distribution network for our robotics customers and our subsystem customers in the robotics marketplace. So we're sort of saying both Western customers and global customers to answer the first part of your question. The second part of your question in terms of the dollar content and there, a typical NV product ASP is perhaps 1 to 2 per sensor. And obviously, there's several sensors used in the precision motion application of human robotics. So we see a potential for several NVE sensors per robot there and that drives a significant revenue from our perspective. So I think there's a big upside.
Unknown Analyst
And by several, do you -- would you say in the tens of sensors or in the hundreds of sense, like just a scale of 20 to 50, like a rough range?
Peter Eames
Certainly, in the tens of centers, I think is fair.
Unknown Analyst
I just had one question. So with the short-term disruption with respect to the second quarter, and some of that revenue getting pulled into the first. Is it fair to -- is it really fair to say when you think about your second half estimates being kind of in line with the first half that you would normalize those first 2 quarters, in other words, it would be somewhere along the midpoint on a quarter-by-quarter basis going forward of the first 2 quarters.
Peter Eames
Yes. That's certainly 1 way to look at it. I think the year-to-date numbers are appropriate, and that's kind of where the estimates came from.
Unknown Analyst
Pete, this is Pete Prevent again. Do you have any more expansion plans? I mean I remember when I was there a few years ago of the new area that you guys expanded. It sounds like you've got equipment selling in that area. Is there a need for additional space? Do you haven't secured any additional buildings where you moved admin into that, and then you're going to use that area in the existing building for production.
Peter Eames
That's right, Pete. Good memory. That is the opt-in that we evaluate. We haven't discussed further expansion plans beyond the space that you saw when you visited. However, that is something obviously that we keep in mind, and we will continue to expand as needed and we'd follow the strategy that you mentioned, which is to move some of the admin off-site and continue to expand by leveraging the infrastructure that we have here within our current building. So we definitely keep those plans of fresh and we'll adapt to them as we need to.
Unknown Analyst
Okay. Great. And it seems like you have a phenomenal Board of Directors are you guys meeting quarterly? And how do you feel they are in supporting your efforts, your growth efforts and any needs that you have in order to continue to grow the company.
Peter Eames
Yes. We have an excellent board, as you mentioned, and we're happy to draw from experience throughout the industry. We expanded our Board to 7. And I think that makes them even stronger. And yes, we meet on a quarterly basis and happy to get the feedback and direction that the Board provides very valuable for the company.
Unknown Analyst
Can you just talk quickly about the contributor sales as effectively -- well, first of all, how has it changed from last quarter? And should I view that as an increase in distributor sales mix being the ability to flex revenue higher but coming at lower margin?
Peter Eames
I think that's a safe assumption. We have a global distribution network, as I mentioned earlier, and they leverage sales for us. So this is a sort of broadest estimate of the sales of the company. It covers the broadest product portfolio for us. And when we see growth there, that's a very good sign for revenue in general. And so we're very happy to see distributor sales increasing and it's a sign of continued attraction of entries products in general, growing -- gaining in the market.
Unknown Analyst
But you're saying as a percent of mix distributor sales had increased quarter-over-quarter?
Peter Eames
It has. It does bob around a little bit and vary from quarter-to-quarter, as you might expect. Certainly, when we have a lower direct customer sales as we did in the last quarter than just our percentage of distributor sales increases. It's common for it to vary somewhat throughout the year. But in general, it's fairly steady usually between something like 1/3 and 2/3 of total revenue.
Unknown Analyst
I just have 2 questions. And first off, congratulations on the new role. I had a question in regards to specifically the distributor sales growth year-over-year and how you see those trends going forward? And then a little bit more color on the first half of the year related to nonmedical sales growth, stripping out Abbott and all those medical sales growth. If you could give any color on that?
Peter Eames
Well, as I mentioned, distributor sales is a pretty broad representation of NVE's product portfolio and when we see growth there, that's a good sign because it's sort of a more general reflection of envies products and sales. And we see that as a very good sign. And then in terms of the distributor sales in general, we're pleased to see that increasing. And I think overall, the growth that we've seen year-to-date and going forward will be a continuation of some of the things we said in the first quarter, and that's growth broadly generally and across NVE's products?
Unknown Analyst
Did I hear correctly that distributor sales grew 67% year-over-year. Did you guys say that in the initial remarks? Or was I mishearing something?
Peter Eames
No, that's correct, Kevin.
Unknown Analyst
Is that for H1? Or is that for Q2?
Peter Eames
That's for Q2.
Unknown Analyst
Do you have an H1 figure for distributor sales year-over-year?
Peter Eames
It's somewhat less than that. I would place it a little bit lower, perhaps in the 40% range.
Unknown Analyst
Okay. So it's -- so distributor sales has accelerated in Q2 versus Q1.
Peter Eames
Correct. Understood. All right. Thank you, Pete.
Unknown Analyst
I have 1 more question. About my question earlier about, I guess, customer diversification. And you were saying how the end of year or the second half of the year's earnings are going to be similar to the first half. Is that correct?
Peter Eames
Correct. Yes.
Unknown Analyst
Is that mix going to be similar to the first half, where it's mostly a few large customers? Or do you believe that the growth is going to come from additional customers like the additional ones that were gained in the first half of the year?
Peter Eames
Yes. We certainly expect revenue to increasingly come from the new customers. And -- that's because the market is continuing to accept our new products, and we'll continue to see growth for that reason -- and so I think there's some short-term optimism as our wafer level chip scale products, new gear centers and others that we've talked about previously continue to grow and and become more representative of the total revenue numbers.
Unknown Analyst
I guess this -- given that, obviously, NVE has very -- I guess, you could say in each technology that isn't very easily replicated and has many applications the biggest barrier to entry or I guess the biggest competitive advantage that NVE and more specifically, the spintronic technology has. And I guess, why other new entrants can't come in and take over in a sense.
Peter Eames
Yes. Barriers to entry include patent portfolio and that prevents competitors from operating in our space. So we have excellent patent coverage in spintronics and -- we think that provides that coverage. We also have trade secrets and expertise within the company that make it very difficult for competitors to do what NVE does and to try to copy the advantages that NVE provides with spintronics. It's a unique technology, we provide benefit using to our customers that's unlike any others. And we think our company is reflective of those advantages.
Okay. Well, the second quarter and excellent growth in revenue for the first half of the year. Our next earnings call will be in January to discuss third quarter results. A replay of this call will be available on the investor events page of our website, www.nve.com and our YouTube channel, youtube.com/nvecorporation.
이 문서에는 사람이 검토한 AI 생성 콘텐츠 또는 AI 번역 콘텐츠가 포함될 수 있습니다. 이는 참고용 및 전반적인 정보를 제공용으로만 제공되며 투자 조언에 해당하지 않습니다.
추천 기사









코멘트 (0)
$ 버튼을 클릭하고, 종목 코드를 입력한 후 주식, ETF 또는 기타 티커를 연결합니다.